Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.

IMPAKT 2017

4 - 6 May 2017

Brussels, Brussels, Belgium

Genetic determinants of breast cancer immune phenotypes

Dr Giuseppe Curigliano - European Institute of Oncology, Milan, Italy

Genetic determinants of breast cancer immune phenotypes ( Dr Giuseppe Curigliano - European Institute of Oncology, Milan, Italy )

IMPAKT conference highlights

Dr Fatima Cardoso - Champalimaud Cancer Center, Lisbon, Portugal

IMPAKT conference highlights ( Dr Fatima Cardoso - Champalimaud Cancer Center, Lisbon, Portugal )

Mutational landscapes in pregnant and non-pregnant breast cancer

Prof Sibylle Loibl - German Breast Cancer Group, Frankfurt, Germany

Mutational landscapes in pregnant and non-pregnant breast cancer ( Prof Sibylle Loibl - German Breast Cancer Group, Frankfurt, Germany )

Resistance to CDK4/6 inhibitors

Dr Nicholas Turner - The Institute of Cancer Research, London, UK

Resistance to CDK4/6 inhibitors ( Dr Nicholas Turner - The Institute of Cancer Research, London, UK )

Deciphering the connection of genetics, immune infiltration and prognosis

Dr Jan Budczies - Charité Universitätsmedizin Berlin, Berlin, Germany

Deciphering the connection of genetics, immune infiltration and prognosis ( Dr Jan Budczies - Charité Universitätsmedizin Berlin, Berlin, Germany )

Genetic vs immune strategies in breast cancer

Prof Fabrice André - Institut Gustave Roussy, Paris, France

Genetic vs immune strategies in breast cancer ( Prof Fabrice André - Institut Gustave Roussy, Paris, France )

Transforming patient care through translational research

Prof Aleix Prat - Hospital Clinic of Barcelona, Barcelona, Spain

Transforming patient care through translational research ( Prof Aleix Prat - Hospital Clinic of Barcelona, Barcelona, Spain )

Mechanisms of resistance to CDK4/6 inhibitors in triple negative breast cancer

Dr Uzma Asghar - The Institute of Cancer Research, London, UK

Mechanisms of resistance to CDK4/6 inhibitors in triple negative breast cancer ( Dr Uzma Asghar - The Institute of Cancer Research, London, UK )

pSTAT3 in luminal breast cancer - results from BIG-2-98 trial

Dr Amir Sonnenblick - Hebrew University Medical Center, Jerusalem, Israel

pSTAT3 in luminal breast cancer - results from BIG-2-98 trial ( Dr Amir Sonnenblick - Hebrew University Medical Center, Jerusalem, Israel )

Increased long-term risk of breast cancer with high intra-tumour ER hetrogeneity

Dr Linda Lindström - University of California at San Francisco, San Francisco...

Increased long-term risk of breast cancer with high intra-tumour ER hetrogeneity ( Dr Linda Lindström - University of California at San Francisco, San Francisco, USA )

GTX-024 for androgen receptor positive breast cancer

Prof Beth Overmoyer - Dana-Farber Cancer Institute, Boston, USA

GTX-024 for androgen receptor positive breast cancer ( Prof Beth Overmoyer - Dana-Farber Cancer Institute, Boston, USA )

Adaptive trial design on breast cancer

Prof Laura Vant Veer - University of California San Francisco, San Francisco...

Adaptive trial design on breast cancer ( Prof Laura Vant Veer - University of California San Francisco, San Francisco, USA )

More from ecancer